3.55

2.74% -0.10

Nutriband Inc (NTRB)

Overview News Price History Discussions Forecast Stock Split

Nutriband Inc stock is currently priced at $3.55, with a 24-hour trading volume of 10,280. It has seen a -2.74% decreased in the last 24 hours and a +16.78% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.72 pivot point. If it approaches the $3.49 support level, significant changes may occur.

Previous Close:

$3.65

Open:

$3.54

24h Volume:

10,280

Market Cap:

$37.49M

Revenue:

$2.09M

Net Income/Loss:

$-5.28M

P/E Ratio:

-6.0169

EPS:

-0.59

Net Cash Flow:

$-3.64M

1W Performance:

-9.67%

1M Performance:

+16.78%

6M Performance:

+83.95%

1Y Performance:

-1.39%

1D Range:

$3.54

$3.82

52W Range:

$1.53

$5.9274

Nutriband Inc Stock (NTRB) Company Profile

Name

Nutriband Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

407 377 6695

Address

121 South Orange Avenue, Suite 1500, Orlando

Employee

Twitter

Next Earnings Date

2024-04-29

Latest SEC Filings

NTRB's Discussions on Twitter

Nutriband Inc Stock (NTRB) Latest News

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Nutriband Inc Stock (NTRB) Financials Data

Nutriband Inc (NTRB) Revenue 2024

NTRB reported a revenue (TTM) of $2.09 million for the quarter ending October 31, 2023, a +2.16% rise year-over-year.

Nutriband Inc (NTRB) Net Income 2024

NTRB net income (TTM) was -$5.28 million for the quarter ending October 31, 2023, a +19.61% increase year-over-year.

Nutriband Inc (NTRB) Cash Flow 2024

NTRB recorded a free cash flow (TTM) of -$3.64 million for the quarter ending October 31, 2023, a -3.73% decrease year-over-year.

Nutriband Inc (NTRB) Earnings per Share 2024

NTRB earnings per share (TTM) was -$0.67 for the quarter ending October 31, 2023, a +16.25% growth year-over-year.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.